WuXi Vaccines opens manufacturing facility in China

28 September 2023
vaccine_shot_jab_booster_big

Suzhou, China-based WuXi Vaccines has announced the launch of its first standalone vaccines facility, in its home city.

The Chinese contract development and manufacturing organization (CDMO) is focused on vaccine discovery, development, and manufacturing, regardless of the vaccine modality.

This broad-based approach has seen the firm develop expertise in protein, virus, VLP, DNA and mRNA or RNA-based vaccine technologies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology